Shanghai, China

Tiejiong Fan


 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2017

where 'Filed Patents' based on already Granted Patents

1 patent (USPTO):

Title: **Innovations by Tiejiong Fan in Antibody Development**

Introduction

Tiejiong Fan is a distinguished inventor based in Shanghai, China, recognized for his significant contributions to the field of biotechnology. His work focuses on the development of human monoclonal antibodies that target the epidermal growth factor receptor (EGFR), which is crucial in the treatment of certain tumors.

Latest Patents

Tiejiong Fan holds a patent for his invention titled "Human anti-human epidermal growth factor receptor antibody and encoding gene and application thereof." This patent outlines a remarkable method involving gene engineering techniques and phage surface display technology to screen anti-human EGFR gene engineering single chain antibodies from a fully synthetic antibody library. The invention facilitates the construction of intact human monoclonal antibodies, which demonstrate a binding affinity of no more than 1 nM with human EGFR.

Career Highlights

Fan's professional journey includes a notable position at Shanghai Saiyuan Biotechnology Co., Ltd., where he applies his expertise in biotechnology. His innovative contributions have led to the development of high-purity antibody proteins that exhibit strong bioactivity in inhibiting tumor growth in models expressing EGFR. The efficacy of these antibodies also extends to the potential treatment of inflammation and autoimmune diseases.

Collaborations

Tiejiong Fan collaborates with prominent colleagues such as Zhiwei Sun and Shuang Hong Wang, leveraging their combined expertise to advance research and development in the field of targeted therapies. This collaborative approach enhances the depth and breadth of scientific inquiry and practical applications related to antibody-based treatments.

Conclusion

Tiejiong Fan's innovations in the realm of human monoclonal antibodies signify a pivotal advancement in biotechnology, particularly for addressing EGFR-targeted tumors and related diseases. His work has the potential to improve therapeutic strategies and patient outcomes, underscoring the importance of continued innovation in this field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…